Urologic Oncology Research Training Grant
泌尿肿瘤学研究培训补助金
基本信息
- 批准号:9749998
- 负责人:
- 金额:$ 31.37万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-08-01 至 2020-07-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): Since its inception in 1999, the primary objective of the T32 Urologic Oncology Research Training Program at Memorial Sloan Kettering Cancer Center (MSKCC) has been to train select urologists for productive careers in translational research in urologic oncology. Dedicated research training in urologic oncology is essential to the mission of the National Cancer Institute (NCI) to reduce morbidity and mortality from genitourinary cancers, which cause about 10% of all cancer-related deaths in the United States and which are expected to rise steadily in incidence as the population ages. An NCI-designated comprehensive cancer center since 1973, MSKCC provides a first-class environment with many unique resources for the training of clinician-scientists, including a high volume of patients with
all types and stages of urologic malignancies, large clinical databases with long-term clinical follow-up, large fresh tumor banks with blood samples, and cutting-edge basic and translational scientific research programs. The T32 Urologic Oncology Research Training Program at MSKCC has been designed to capitalize on these unique research training opportunities. For the proposed funding period, the new Program Director and T32 Committee have developed an interactive, multidisciplinary research training strategy that integrates the following: (1) a multidisciplinary faculty of basic, clinical, and translational researchers spanning the discipline of surgery, molecular pharmacology and chemistry, medicine, cancer biology and genetics, molecular radiology, biostatistics and epidemiology, and laboratory medicine, (2) an intensive mentored research practicum tailored to the T32 trainee's research interests and goals, (3) a core curriculum of required didactic and discussion-based courses to enhance the quality of the hands- on research training, (4) structured career development workshops in grant writing and career development awards, and (5) elective activities that will allow T32 trainees to further immerse themselves in the world of cancer research and to network with peers and established leaders. Each year, 2 highly committed postdoctoral trainees from the Urologic Oncology Fellowship Program at MSKCC are selected for the T32 Urologic Oncology Research Training Program. They must have an MD, must have completed residency training in urology, and must be board-eligible urologists. These 2 trainees are supported by this T32 training grant during 2 years dedicated to urologic oncology research training, with appointment to the 2nd year contingent on suitable progress. At the completion of their training, graduates of theT32 Urologic Oncology Research Training Program are expected to be attractive candidates for junior faculty appointments at research-focused academic organizations. In the past 5 years, 88% of T32 trainee graduates have matriculated to faculty positions at academic institutions and are engaged in laboratory and/or clinical research aimed at understanding and overcoming genitourinary cancers.
描述(由申请人提供):自1999年成立以来,纪念斯隆-凯特琳癌症中心(MSKCC)的T32泌尿系统肿瘤学研究培训计划的主要目标是培训精选的泌尿外科医生,使其在泌尿系统肿瘤学的翻译研究方面取得丰硕的职业生涯。国家癌症研究所(NCI)的使命是减少泌尿生殖系癌症的发病率和死亡率,泌尿生殖系癌症约占美国所有癌症相关死亡的10%,随着人口老龄化,发病率预计将稳步上升。MSKCC自1973年以来一直是NCI指定的综合性癌症中心,为临床医生和科学家的培训提供了一流的环境和许多独特的资源,包括大量的
所有类型和分期的泌尿系恶性肿瘤,具有长期临床随访的大型临床数据库,具有血液样本的大型新鲜肿瘤库,以及尖端基础和转化性科学研究计划。MSKCC的T32泌尿系统肿瘤研究培训计划旨在利用这些独特的研究培训机会。在拟议的资助期间,新的项目主任和T32委员会制定了一项互动的多学科研究培训战略,包括以下内容:(1)基础、临床和翻译研究人员的多学科学院,涵盖外科、分子药理学和化学、医学、癌症生物学和遗传学、分子放射学、生物统计学和流行病学以及实验室医学等学科;(2)针对T32学员的研究兴趣和目标而定制的强化指导研究实践;(3)必要的教学和基于讨论的课程的核心课程,以提高实践研究培训的质量,(4)在赠款撰写和职业发展奖方面举办有组织的职业发展研讨会,以及(5)选修活动,让T32受训人员进一步沉浸在癌症研究的世界中,并与同行和知名领导者建立网络。每年,来自MSKCC泌尿系统肿瘤学奖学金项目的2名高度致力于博士后培训的博士后学员被选入T32泌尿系统肿瘤研究培训项目。他们必须拥有医学博士学位,必须完成泌尿外科住院医师培训,并且必须是具有董事会资格的泌尿科医生。这两名学员是由T32培训基金资助的,为期2年,致力于泌尿外科肿瘤学研究培训,并根据适当的进展任命到第二年。在完成培训后,T32泌尿外科肿瘤研究培训计划的毕业生有望成为研究型学术组织初级教员的有吸引力的候选人。在过去的5年里,88%的T32实习毕业生进入了学术机构的教职,从事旨在了解和克服泌尿生殖系癌症的实验室和/或临床研究。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Brett Stewart Carver其他文献
Brett Stewart Carver的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Brett Stewart Carver', 18)}}的其他基金
PSMA’s enzymatic activity as new target for Prostate Cancer diagnosis and therapy
PSMA 酶活性成为前列腺癌诊断和治疗的新靶点
- 批准号:
10436370 - 财政年份:2021
- 资助金额:
$ 31.37万 - 项目类别:
PSMA’s enzymatic activity as new target for Prostate Cancer diagnosis and therapy
PSMA 酶活性成为前列腺癌诊断和治疗的新靶点
- 批准号:
10311708 - 财政年份:2021
- 资助金额:
$ 31.37万 - 项目类别:
PSMA’s enzymatic activity as new target for Prostate Cancer diagnosis and therapy
PSMA 酶活性成为前列腺癌诊断和治疗的新靶点
- 批准号:
10656491 - 财政年份:2021
- 资助金额:
$ 31.37万 - 项目类别:
Project 3: Defining the appropriate context for targeting kinase signaling in combination with androgen receptor blockade to enhance therapeutic response in metastatic prostate cancer
项目 3:确定靶向激酶信号传导与雄激素受体阻断相结合的适当背景,以增强转移性前列腺癌的治疗反应
- 批准号:
10250363 - 财政年份:2017
- 资助金额:
$ 31.37万 - 项目类别:
Project 3: Defining the appropriate context for targeting kinase signaling in combination with androgen receptor blockade to enhance therapeutic response in metastatic prostate cancer
项目 3:确定靶向激酶信号传导与雄激素受体阻断相结合的适当背景,以增强转移性前列腺癌的治疗反应
- 批准号:
10005212 - 财政年份:2017
- 资助金额:
$ 31.37万 - 项目类别:
Defining Response and Resistance to PI3K and AR inhibition in Prostate Cancer
定义前列腺癌对 PI3K 和 AR 抑制的反应和抵抗
- 批准号:
8760826 - 财政年份:2014
- 资助金额:
$ 31.37万 - 项目类别:
Defining Response and Resistance to PI3K and AR inhibition in Prostate Cancer
定义前列腺癌对 PI3K 和 AR 抑制的反应和抵抗
- 批准号:
9331474 - 财政年份:2014
- 资助金额:
$ 31.37万 - 项目类别:
Defining Response and Resistance to PI3K and AR inhibition in Prostate Cancer
定义前列腺癌对 PI3K 和 AR 抑制的反应和抵抗
- 批准号:
8926908 - 财政年份:2014
- 资助金额:
$ 31.37万 - 项目类别:
Defining Response and Resistance to PI3K and AR inhibition in Prostate Cancer
定义前列腺癌对 PI3K 和 AR 抑制的反应和抵抗
- 批准号:
9118938 - 财政年份:2014
- 资助金额:
$ 31.37万 - 项目类别:
Project 2: Overcoming Microenvironment-Mediated Resistance to AR Pathway Inhibition in High-Risk Prostate Cancer
项目 2:克服微环境介导的高危前列腺癌 AR 通路抑制耐药性
- 批准号:
10707969 - 财政年份:2001
- 资助金额:
$ 31.37万 - 项目类别: